The	O
prognostic	O
value	O
of	O
cytotoxic	B:C0111208
T	I:C0111208
-	I:C0111208
lymphocyte	I:C0111208
antigen	I:C0111208
4	I:C0111208
in	O
cancers	O
:	O
a	O
systematic	O
review	I:C1955832
and	O
meta-analysis	O
.	O

The	O
prognostic	O
value	O
of	O
cytotoxic	O
T	I:C0111208
-	I:C0111208
lymphocyte	I:C0111208
antigen	I:C0111208
4	I:C0111208
in	O
cancers	B:C0006826
:	O
a	O
systematic	O
review	I:C1955832
and	O
meta-analysis	O
.	O

The	O
prognostic	O
value	O
of	O
cytotoxic	O
T	I:C0111208
-	I:C0111208
lymphocyte	I:C0111208
antigen	I:C0111208
4	I:C0111208
in	O
cancers	O
:	O
a	O
systematic	B:C1955832
review	I:C1955832
and	O
meta-analysis	O
.	O

The	O
prognostic	O
value	O
of	O
cytotoxic	O
T	I:C0111208
-	I:C0111208
lymphocyte	I:C0111208
antigen	I:C0111208
4	I:C0111208
in	O
cancers	O
:	O
a	O
systematic	O
review	I:C1955832
and	O
meta-analysis	B:C0920317
.	O

The	O
outcomes	B:C0543472
of	O
studies	O
analyzing	O
the	O
prognostic	O
role	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
in	O
cancers	O
are	O
controversial	O
.	O

The	O
outcomes	O
of	O
studies	O
analyzing	B:C0936012
the	O
prognostic	O
role	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
in	O
cancers	O
are	O
controversial	O
.	O

The	O
outcomes	O
of	O
studies	O
analyzing	O
the	O
prognostic	O
role	O
of	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
in	O
cancers	O
are	O
controversial	O
.	O

The	O
outcomes	O
of	O
studies	O
analyzing	O
the	O
prognostic	O
role	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
in	O
cancers	B:C0006826
are	O
controversial	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
our	O
meta	B:C0920317
-	I:C0920317
analysis	I:C0920317
was	O
to	O
clarify	O
the	O
correlation	O
between	O
CTLA	O
-	I:C0111208
4	I:C0111208
expression	O
and	O
OS	O
in	O
different	O
cancer	O
cases	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
our	O
meta	O
-	I:C0920317
analysis	I:C0920317
was	O
to	O
clarify	O
the	O
correlation	O
between	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
expression	O
and	O
OS	O
in	O
different	O
cancer	O
cases	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
our	O
meta	O
-	I:C0920317
analysis	I:C0920317
was	O
to	O
clarify	O
the	O
correlation	O
between	O
CTLA	O
-	I:C0111208
4	I:C0111208
expression	O
and	O
OS	O
in	O
different	O
cancer	B:C0006826
cases	O
.	O

Relevant	O
literature	B:C0023866
was	O
searched	O
using	O
PubMed	O
,	O
EMBASE	O
,	O
Web	O
of	I:C0282574
Science	I:C0282574
,	O
and	O
the	O
Cochrane	O
Library	I:C0282574
.	O

Relevant	O
literature	O
was	O
searched	O
using	O
PubMed	B:C1138432
,	O
EMBASE	O
,	O
Web	O
of	I:C0282574
Science	I:C0282574
,	O
and	O
the	O
Cochrane	O
Library	I:C0282574
.	O

Relevant	O
literature	O
was	O
searched	O
using	O
PubMed	O
,	O
EMBASE	B:C0282574
,	O
Web	O
of	I:C0282574
Science	I:C0282574
,	O
and	O
the	O
Cochrane	O
Library	I:C0282574
.	O

Relevant	O
literature	O
was	O
searched	O
using	O
PubMed	O
,	O
EMBASE	O
,	O
Web	B:C0282574
of	I:C0282574
Science	I:C0282574
,	O
and	O
the	O
Cochrane	O
Library	I:C0282574
.	O

Relevant	O
literature	O
was	O
searched	O
using	O
PubMed	O
,	O
EMBASE	O
,	O
Web	O
of	I:C0282574
Science	I:C0282574
,	O
and	O
the	O
Cochrane	B:C0282574
Library	I:C0282574
.	O

The	O
clinicopathological	B:C0030667
features	I:C0030667
,	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
collected	O
from	O
these	O
studies	O
and	O
were	O
analyzed	O
using	O
Stata	O
version	I:C0282574
12.0	I:C0282574
software	I:C0282574
.	O

The	O
clinicopathological	O
features	I:C0030667
,	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
collected	O
from	O
these	O
studies	O
and	O
were	O
analyzed	B:C0936012
using	O
Stata	O
version	I:C0282574
12.0	I:C0282574
software	I:C0282574
.	O

The	O
clinicopathological	O
features	I:C0030667
,	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
collected	O
from	O
these	O
studies	O
and	O
were	O
analyzed	O
using	O
Stata	B:C0282574
version	I:C0282574
12.0	I:C0282574
software	I:C0282574
.	O

The	O
pooled	O
HR	O
values	O
showed	O
no	O
significant	O
correlation	O
between	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
expression	O
levels	O
and	O
OS	O
in	O
relation	O
to	O
tumors	O
(	O
HR	O
:	O
1.24	O
,	O
95	O
%	O
CI	O
:	O
0.98	O
-1.56	O
,	O
I2	O
=	O
71.7	O
%	O
,	O
P	O
=	O
0.000	O
)	O
.	O

The	O
pooled	O
HR	O
values	O
showed	O
no	O
significant	O
correlation	O
between	O
CTLA	O
-	I:C0111208
4	I:C0111208
expression	O
levels	O
and	O
OS	O
in	O
relation	O
to	O
tumors	B:C0027651
(	O
HR	O
:	O
1.24	O
,	O
95	O
%	O
CI	O
:	O
0.98	O
-1.56	O
,	O
I2	O
=	O
71.7	O
%	O
,	O
P	O
=	O
0.000	O
)	O
.	O

Further	O
subgroup	B:C1515021
analyses	O
were	O
conducted	O
and	O
categorized	O
by	O
experimental	O
methods	I:C0871738
,	O
CTLA	O
-	I:C0111208
4	I:C0111208
sources	O
and	O
cancer	O
types	O
.	O

Further	O
subgroup	O
analyses	B:C0936012
were	O
conducted	O
and	O
categorized	O
by	O
experimental	O
methods	I:C0871738
,	O
CTLA	O
-	I:C0111208
4	I:C0111208
sources	O
and	O
cancer	O
types	O
.	O

Further	O
subgroup	O
analyses	O
were	O
conducted	O
and	O
categorized	O
by	O
experimental	B:C0871738
methods	I:C0871738
,	O
CTLA	O
-	I:C0111208
4	I:C0111208
sources	O
and	O
cancer	O
types	O
.	O

Further	O
subgroup	O
analyses	O
were	O
conducted	O
and	O
categorized	O
by	O
experimental	O
methods	I:C0871738
,	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
sources	O
and	O
cancer	O
types	O
.	O

The	O
survey	B:C0038951
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	O
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	O
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	B:C0752046
subgroup	O
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	O
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	O
subgroup	B:C1515021
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	O
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	B:C1515021
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	O
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	O
analyzing	B:C0936012
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	O
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	B:C0032520
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	O
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
1.86	O
)	O
and	O
flow	B:C0016263
cytometry	I:C0016263
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49	O
-	O
5.14	O
)	O
.	O

In	O
addition	O
,	O
our	O
analysis	B:C0936012
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	B:C0003323
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	B:C0024264
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	B:C0003323
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	B:C0024264
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	B:C0085358
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	B:C0024264
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	B:C0111208
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	B:C0085358
+	I:C0085358
lymphocytes	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
sur	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD4	O
+	I:C0003323
lymphocytes	O
,	O
in	O
CTLA	O
-	I:C0111208
4	I:C0111208
+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	O
,	O
and	O
sur	O
CTLA	O
-	I:C0111208
4+	I:C0111208
CD8	O
+	I:C0085358
lymphocytes	B:C0024264
.	O

Knowledge	O
of	O
the	O
effects	O
of	O
CTLA	B:C0111208
-	I:C0111208
4	I:C0111208
could	O
potentially	O
be	O
used	O
to	O
effectively	O
guide	O
appropriate	O
prognosis	O
and	O
therapeutic	O
strategies	I:C0087111
in	O
cancer	O
patients	O
.	O

Knowledge	O
of	O
the	O
effects	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
could	O
potentially	O
be	O
used	O
to	O
effectively	O
guide	O
appropriate	O
prognosis	B:C3854082
and	O
therapeutic	O
strategies	I:C0087111
in	O
cancer	O
patients	O
.	O

Knowledge	O
of	O
the	O
effects	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
could	O
potentially	O
be	O
used	O
to	O
effectively	O
guide	O
appropriate	O
prognosis	O
and	O
therapeutic	B:C0087111
strategies	I:C0087111
in	O
cancer	O
patients	O
.	O

Knowledge	O
of	O
the	O
effects	O
of	O
CTLA	O
-	I:C0111208
4	I:C0111208
could	O
potentially	O
be	O
used	O
to	O
effectively	O
guide	O
appropriate	O
prognosis	O
and	O
therapeutic	O
strategies	I:C0087111
in	O
cancer	B:C0006826
patients	O
.	O

